Harnessing the Power of CannabinoidsTM
Led by a world class team, BayMedica is developing an efficient and scalable biosynthetic platform to deliver a portfolio of natural cannabinoids including CBC, CBN and CBG as well as novel cannabinoid analogs for life science, pharmaceutical, nutraceutical, cosmetic and animal health applications.
The BayMedica Platform
We are developing the BayMedica platform and process to bring the benefits of cannabinoids to consumers and animals without the drawbacks of traditional methods that involve extracting these therapeutic compounds from cannabis.
Instead of the time consuming process of growing hemp or marijuana which uses valuable arable land and water resources, we use the same yeast that is used to brew beer to bio-prepare cannabinoids. We do this through a patent-pending process by engineering these yeast to make cannabinoids that are identical to the natural compounds found in plants.
BayMedica Products
.
ProDiolTM
Our ProDiol family of natural pharmaceutical-grade, cannabinoids will be available as individual and custom formulations for inclusion into consumer products.
.
PureDiolTM
Our PureDiol family of products feature 95+% pure, ultra-rare, pharmaceutical-grade cannabinoids and novel cannabinoid analogs for pharmaceutical, life-science, research and testing applications.
Our Team
Shane Johnson, MD
Co-Founder, President & CEO
Dr. Johnson is co-founder of a Nevada cannabis cultivator and manufacturer, with extensive experience in strategy and startup management. He holds a BS in neuroscience from Brown University and an MD from Stanford University.
Philip Barr, PhD
Co-Founder, Chief Scientific Officer
Dr. Barr is an expert in polyketide biosynthesis in yeast (cannabinoids are members of the polyketide family) with over 50 patents, 200 manuscripts, and multiple commercial products. He holds a PhD in organic chemistry with over 30 years industry experience.
Charles Marlowe, PhD
Co-Founder, Director of Chemistry
Dr. Marlowe has 25 patents issued and over 30 publications. He has been instrumental in developing small molecule therapeutics. He holds a PhD in organic chemistry from UC Berkeley.
Dave Kent
VP Corporate Development
Jim Kealey, PhD
VP Research & Development
Dr. Kealey has extensive experience in synthetic biology and polyketide synthesis. He has managed large teams and holds a PhD in pharmaceutical chemistry from UCSF.
Chris Meiering, PhD
VP - Commercialization
Dr. Meiering holds a PhD in microbiology from the University of Washington and has over 20 years experience in the companion animal industry.
Jianping Sun, PhD
Director of Molecular Biology
Dr. Sun earned a PhD in biochemistry and molecular biology from USTC – China. She is experienced in fermentation, metabolic engineering and systems biology.